2021 District Days

In 2016, Congress allocated $0 in funding dedicated to kidney cancer research. Through the power of advocacy, we have raised that number to $135 million in five years. Our grassroots army met on August 9-10 for our second District Days event, where we asked Congress to continue funding lifesaving research for kidney cancer patients. 

NO EXPERIENCE NECESSARY!

You have missed this year’s event, but there are plenty of other opportunities to get involved, sign up to our newsletter and receive up to date information.

All patients, families, caregivers, friends, and medical professionals are welcome. Advocates meet virtually with their representatives and Congressional staff in their home districts to ask for research funding.

We provide training with Advocacy 101, a detailed guide to help you know what to expect and how to talk to your representatives about kidney cancer research funding. You receive a meeting schedule, talking points, scripts you can use if you would like, and leave-behind documents.

District Days are powered by

in partnership with

WE NEED YOU

This money isn’t a given. We’ve had to fight for it, year after year. We provide our advocates with training and a toolkit so that you can share your story with Congressional representatives in small meetings. You’ll help them understand the impact of kidney cancer on people’s lives and the urgent need for a cure. Join us and make your voice heard!

For Patients

Advocacy

Research

Join Our Grassroots Army

We know that awareness of kidney cancer and its impact on many lives leads to a sense of urgency, a desire for solutions. Awareness leads to advocacy, and advocacy — joining to speak as one voice — leads to funding and research. That’s how we get to cures.

We just published our August newsletter, filled with exciting #kidneycancer research updates, news, and events. Don't miss a very special feature highlighting an inspiring member of our community. 

Have a great weekend! 

https://conta.cc/3sRMguh

We just published our August newsletter, filled with exciting #kidneycancer research updates, news, and events. Don't miss a very special feature highlighting an inspiring member of our community.

Have a great weekend!

https://conta.cc/3sRMguh
...

7 2
REMINDER: Do you have questions about participating in clinical trials and how to find trials for you? Do you know the risks and benefits? We are hosting a special Facebook Live with a medical oncologist and clinical trial patient to answer all your questions live, including:

• What is a clinical trial?
• Where do I find clinical trials for kidney cancer?
• What are important questions to ask about a trial?
• What is informed consent?
• What are good clinical practices?
• What can patients expect during a trial?
• What are the risks and benefits of participating in a trial?
• What is the difference between participating at an academic institution versus a freestanding clinical research organization (CRO)?

Will you join us? RSVP now so you get a Facebook notification when we go live: https://fb.me/e/1JfopJa6J

REMINDER: Do you have questions about participating in clinical trials and how to find trials for you? Do you know the risks and benefits? We are hosting a special Facebook Live with a medical oncologist and clinical trial patient to answer all your questions live, including:

• What is a clinical trial?
• Where do I find clinical trials for kidney cancer?
• What are important questions to ask about a trial?
• What is informed consent?
• What are good clinical practices?
• What can patients expect during a trial?
• What are the risks and benefits of participating in a trial?
• What is the difference between participating at an academic institution versus a freestanding clinical research organization (CRO)?

Will you join us? RSVP now so you get a Facebook notification when we go live: https://fb.me/e/1JfopJa6J
...

5 0
🚨🚨 RESEARCH NEWS
Lenvantinib (by Eisai) + Keytruda (by Merck) is now 
U.S. Food and Drug Administration approved for #kidneycancer. Wonderful to have this powerful new combo as a treatment option for patients with advanced #RCC!

Dr. Toni Choueiri of Dana-Farber Cancer Institute says, "This is another important combination option for advanced kidney cancer patients. The results in term of responses including complete responders are the highest to date, albeit with a bit different patient populations. The hope is to continue building on doublets, like pembro/Len with other active drugs, that are able to induce more deep and sustainable remissions."

Great news! 

More information here: https://cancernetwork.com/view/pembrolizumab-lenvatinib-approved-by-the-fda-for-the-treatment-of-first-line-advanced-rcc

🚨🚨 RESEARCH NEWS
Lenvantinib (by Eisai) + Keytruda (by Merck) is now
U.S. Food and Drug Administration approved for #kidneycancer. Wonderful to have this powerful new combo as a treatment option for patients with advanced #RCC!

Dr. Toni Choueiri of Dana-Farber Cancer Institute says, "This is another important combination option for advanced kidney cancer patients. The results in term of responses including complete responders are the highest to date, albeit with a bit different patient populations. The hope is to continue building on doublets, like pembro/Len with other active drugs, that are able to induce more deep and sustainable remissions."

Great news!

More information here: https://cancernetwork.com/view/pembrolizumab-lenvatinib-approved-by-the-fda-for-the-treatment-of-first-line-advanced-rcc
...

6 0
We lose almost 40 people per day to kidney cancer in the United States. The need for research funding is urgent.

For #DistrictDays, the #kidneycancer community is meeting with members of #Congress all over the United States to ask for robust funding of kidney cancer research. 

We want Congress to 

1. Maintain the $50 million currently allocated for KCRP for
Fiscal Year 2022. 
2. Increase the NIH budget by $3.5 billion for Fiscal Year 2022. 
3. Support the creation of ARPA-H (the Advanced Research
Projects Agency - Health) at NIH with an additional $3 billion.
4. Continue supporting legislative initiatives that contribute to
robust, sustainable funding for medical research.
5. Continue to incorporate the patient perspective on legislative policy matters.

Thank you to the many delegates from all over the country who are speaking on behalf of patients, caregivers, friends, and family members today. Thank you to doctors and researchers from the medical community who've made time today to lift their voices with ours. 

Let's work together to #fundthecure.

#AcceleratingCures

We lose almost 40 people per day to kidney cancer in the United States. The need for research funding is urgent.

For #DistrictDays, the #kidneycancer community is meeting with members of #Congress all over the United States to ask for robust funding of kidney cancer research.

We want Congress to

1. Maintain the $50 million currently allocated for KCRP for
Fiscal Year 2022.
2. Increase the NIH budget by $3.5 billion for Fiscal Year 2022.
3. Support the creation of ARPA-H (the Advanced Research
Projects Agency - Health) at NIH with an additional $3 billion.
4. Continue supporting legislative initiatives that contribute to
robust, sustainable funding for medical research.
5. Continue to incorporate the patient perspective on legislative policy matters.

Thank you to the many delegates from all over the country who are speaking on behalf of patients, caregivers, friends, and family members today. Thank you to doctors and researchers from the medical community who've made time today to lift their voices with ours.

Let's work together to #fundthecure.

#AcceleratingCures
...

13 0
Thank you to Senator Grassley's office for meeting with us today. Here, KidneyCAN President and #kidneycancer survivor Bryan Lewis, along with our friend and patient Shari, and Dr. Zakharia speak up about the need for robust research funding. 

76,000+ will be diagnosed in 2021. 
14,000 Americans will lose their lives to kidney cancer this year. 

It's urgent! Let's #fundthecure.

#acceleratingcures #districtdays

Thank you to Senator Grassley's office for meeting with us today. Here, KidneyCAN President and #kidneycancer survivor Bryan Lewis, along with our friend and patient Shari, and Dr. Zakharia speak up about the need for robust research funding.

76,000+ will be diagnosed in 2021.
14,000 Americans will lose their lives to kidney cancer this year.

It's urgent! Let's #fundthecure.

#acceleratingcures #districtdays
...

20 2
Here we go! 

#KidneyCancer advocates across the #USA are speaking with #onevoice today. We're asking #Congress to #fundthecure with robust research funding for the National Institutes of Health, the Congressionally Directed Medical Research Programs - Kidney Cancer Research Program, and ARPA-H, which will devote specific funding to cancer research initiatives.

We lose 40 people per day to kidney cancer. This is urgent. The time is NOW.

Here we go!

#KidneyCancer advocates across the #USA are speaking with #onevoice today. We're asking #Congress to #fundthecure with robust research funding for the National Institutes of Health, the Congressionally Directed Medical Research Programs - Kidney Cancer Research Program, and ARPA-H, which will devote specific funding to cancer research initiatives.

We lose 40 people per day to kidney cancer. This is urgent. The time is NOW.
...

12 2
Recently diagnosed with COVID-19? Bristol Myers Squibb's COVID treatment trial -- mAb Duo -- is now up and live on the NIH Rise Above COVID site for patients. This Phase 2 trial is for COVID-positive patients experiencing symptoms who are standard risk to progressing (not only high risk patients). The Phase 2 trial enrollment is now live in the US at 53 sites.

You may already know that we at KidneyCAN are big proponents for clinical trials. Here's why:

Why should I join a clinical trial?
Clinical trials are part of clinical research and at the heart of all medical advances. Clinical trials look at new ways to prevent, detect, or treat disease.

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments.

The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses.

People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.

Clinical trials offer hope for many people and an opportunity to help researchers find better treatments for others in the future.

Recently diagnosed with COVID-19? Bristol Myers Squibb's COVID treatment trial -- mAb Duo -- is now up and live on the NIH Rise Above COVID site for patients. This Phase 2 trial is for COVID-positive patients experiencing symptoms who are standard risk to progressing (not only high risk patients). The Phase 2 trial enrollment is now live in the US at 53 sites.

You may already know that we at KidneyCAN are big proponents for clinical trials. Here's why:

Why should I join a clinical trial?
Clinical trials are part of clinical research and at the heart of all medical advances. Clinical trials look at new ways to prevent, detect, or treat disease.

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments.

The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses.

People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.

Clinical trials offer hope for many people and an opportunity to help researchers find better treatments for others in the future.
...

4 0
We’d love to have you for Kidney Cancer District Advocacy Days! 

You don’t need any prior experience or special skills. We provide you with training and a toolkit so that you can share your story with those who make decisions about research funding. 

You’ll help them understand the impact of kidney cancer on people’s lives and the urgent need for a cure. 

Join us and make your voice heard!

Register at https://kidneycan.org/2021-district-days/

We’d love to have you for Kidney Cancer District Advocacy Days!

You don’t need any prior experience or special skills. We provide you with training and a toolkit so that you can share your story with those who make decisions about research funding.

You’ll help them understand the impact of kidney cancer on people’s lives and the urgent need for a cure.

Join us and make your voice heard!

Register at https://kidneycan.org/2021-district-days/
...

3 0
We’d love to have you for #KidneyCancer District Advocacy Days! You don’t need any prior experience or special skills. We provide you with training and a toolkit so that you can share your story with those who make decisions about research funding. You’ll help them understand the impact of kidney cancer on people’s lives and the urgent need for a cure. 

Join us and make your voice heard!

Register at https://kidneycan.org/2021-district-days/

We’d love to have you for #KidneyCancer District Advocacy Days! You don’t need any prior experience or special skills. We provide you with training and a toolkit so that you can share your story with those who make decisions about research funding. You’ll help them understand the impact of kidney cancer on people’s lives and the urgent need for a cure.

Join us and make your voice heard!

Register at https://kidneycan.org/2021-district-days/
...

6 0
Did you miss our LIVE viewing of "Kidney Cancer: Getting Back on Track After Treatment"? You can still watch the segment here!

https://fb.watch/v/HbgmOw6J/

Did you miss our LIVE viewing of "Kidney Cancer: Getting Back on Track After Treatment"? You can still watch the segment here!

https://fb.watch/v/HbgmOw6J/
...

5 0

KidneyCAN is a registered 501(c)(3) nonprofit and does not receive any funding through the Congressionally Directed Medical Research Programs (CDMRP) or KCRP (Kidney Cancer Research Program). Our work is funded by grassroots donors in the kidney cancer community. 

WHO WE ARE →

WHAT WE DO →

OUR STORIES →

THE KIDNEY CANCER COMMUNITY →

SCIENTIFIC ADVISORY BOARD →

KIDNEYCAN NEWS →

DONATE →

CONTACT →

Latest News

Shari Stonacek: So Many Reasons to Live

Shari Stonacek: So Many Reasons to Live

Shari Stonacek is living with Stage IV kidney cancer. She is pictured here (center) with her family from left to right: daughter Joycin, daughter Jasmin, son-in-law Jordan, daughter-in-law Rachel holding grandson Landon, son Justin, Shari, husband Troy, daughter Joslin holding granddaughter...

JOIN OUR COMMUNITY →

RAISING AWARENESS →

BE AN ADVOCATE →

KIDNEYCAN NEWS →

DONATE →

CONTACT →

Latest News

District Days 2021: Speaking with One Voice

District Days 2021: Speaking with One Voice

Our Ask: Fund Kidney Cancer Research We lose almost 40 people per day to kidney cancer in the United States. The need for research funding is urgent.For District Days, the kidney cancer community met with members of Congress all over the United States to ask for robust funding of kidney cancer...

FACING KIDNEY CANCER →

DIAGNOSIS →

BUILDING A CARE TEAM →

LEARN ABOUT CLINICAL TRIALS →

LIVING WELL WITH KIDNEY CANCER →

DONATE →

CONTACT →

Latest News

Shari Stonacek: So Many Reasons to Live

Shari Stonacek: So Many Reasons to Live

Shari Stonacek is living with Stage IV kidney cancer. She is pictured here (center) with her family from left to right: daughter Joycin, daughter Jasmin, son-in-law Jordan, daughter-in-law Rachel holding grandson Landon, son Justin, Shari, husband Troy, daughter Joslin holding granddaughter...

KCRS →

RESEARCH OPPORTUNITIES →

ADVOCATE WITH KIDNEYCAN →

KIDNEYCAN NEWS →

DONATE →

CONTACT →

Latest News

District Days 2021: Speaking with One Voice

District Days 2021: Speaking with One Voice

Our Ask: Fund Kidney Cancer Research We lose almost 40 people per day to kidney cancer in the United States. The need for research funding is urgent.For District Days, the kidney cancer community met with members of Congress all over the United States to ask for robust funding of kidney cancer...

SUPPORT OUR WORK →

FUNDRAISE FOR KIDNEYCAN →

DONATE →

CONTACT →

Latest News

Shari Stonacek: So Many Reasons to Live

Shari Stonacek: So Many Reasons to Live

Shari Stonacek is living with Stage IV kidney cancer. She is pictured here (center) with her family from left to right: daughter Joycin, daughter Jasmin, son-in-law Jordan, daughter-in-law Rachel holding grandson Landon, son Justin, Shari, husband Troy, daughter Joslin holding granddaughter...